Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms
Launched by METHODIST HEALTH SYSTEM · Jul 6, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how some patients with cerebral aneurysms respond to a medication called clopidogrel. Clopidogrel is used to help prevent blood clots, but some people may react to it differently, which is known as "hyper-responsiveness." The goal is to understand how common this is among patients treated at Methodist Dallas Medical Center and what outcomes they experience.
To participate in this study, you need to be at least 18 years old and have been diagnosed with a cerebral aneurysm. If you meet these criteria and have been treated with clopidogrel before any procedures, you may be eligible. Those who join the study will help researchers gather important information about how clopidogrel affects patients with cerebral aneurysms, which could lead to better treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 years or older Diagnosed with cerebral aneurysms (i.e. ICD-10 i67.1) Pre-intervention treatment with clopidogrel
- Exclusion Criteria:
- • Does not meet inclusion criteria specified in 3.1
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported